- Home
- IBTA vs KALV Comparison
IBTA vs KALV Comparison
Compare IBTA & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | KALV |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.2M | 551.2M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBTA | KALV |
|---|---|---|
| Price | $22.37 | $14.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $37.38 | $30.00 |
| AVG Volume (30 Days) | 354.7K | ★ 1.2M |
| Earning Date | 02-25-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 395.09 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $352,243,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $9.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.60 | $7.30 |
| 52 Week High | $76.00 | $19.00 |
Technical Indicators
Market Signals| Indicator | IBTA | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 45.69 |
| Support Level | $21.30 | $15.77 |
| Resistance Level | $23.32 | $19.00 |
| Average True Range (ATR) | 0.80 | 1.09 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 49.13 | 1.92 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.